Delcath Systems Inc Stock, NASDAQ:DCTH
1633 Broadway, Suite 22 C, New York, New York 10019
United States of America
Number of Employees: 36
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.